RxDoctor Payments Data

John Hudson, MD

Hematology & Oncology · Augusta, GANPI 1700863438

Payments from drug & device makers

$3,072in general payments, 2019–2025

Across 152 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$564
  • Johnson & Johnson$344
  • Pfizer$205
  • Siemens Medical Solutions USA, Inc.$163
  • Daiichi Sankyo Inc.$161
  • Sanofi$160
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$2,76090%
  • Education$31210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,072 in reported general payments places this provider in the 35th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$2,449,793
Medicare patients
758
Services billed
150,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax54$497,028
OjjaaraMomelotinib Dihydrochloride13$341,361
BrukinsaZanubrutinib13$194,474
ImbruvicaIbrutinib11$186,147
XtandiEnzalutamide12$152,108
EliquisApixaban101$78,222
XareltoRivaroxaban16$22,404
Exemestane30$6,104
Abiraterone Acetate11$3,217
Fentanyl14$2,479
Megestrol Acetate18$1,478
Hydroxyurea45$1,389
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen39$1,335
Ondansetron Hcl37$1,159
Oxycodone Hcl46$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$13$497,02854 claims
GSKOjjaara$31$341,36113 claims
Beigene USA, Inc.Brukinsa$11$194,47413 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$30$186,14711 claims
Astellas Pharma US IncXtandi$63$152,10812 claims
PfizerEliquis$205$78,222101 claims
Johnson & JohnsonXarelto$344$22,40416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →